Heart BMJ

MARCH 26, 2025

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. Among patients with myocardial infarction, a 1-SD increase in pulse pressure was associated with a 1.60-fold

Aortic valve 52

Aortic valve Myocardial Infarction Preserved Ejection Fraction Heart Failure 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

European Journal of Heart Failure

DECEMBER 28, 2023

Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. All had no evidence of HF or myocardial infarction prior to completion of the ETT. Thus, we evaluated the association between CRF and HFpEF incidence.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Article 40

Circulation: Heart Failure

NOVEMBER 25, 2024

Spironolactone improved outcomes in patients with severely symptomatic HF with reduced ejection fraction, and later, eplerenone expanded the benefits to patients with mildly symptomatic HF with reduced ejection fraction and myocardial infarction complicated by HF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

Patients diagnosed with reduced ejection fraction (HFrEF) and with heart failure with mildly reduced ejection fraction (HFmrEF) were treated with Vericiguat combined with “ARNI, BB, MRA, SGLT2i” therapy. vs. 43.1 ± 8.5%, P < 0.01), LVEDD (60.5 ± 8.1 vs. 58.2 ± 7.3 mm, mm, P < 0.01), NT-proBNP (4,567.8 ± 5,163.9

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

DAIC

FEBRUARY 29, 2024

ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Circulation

NOVEMBER 11, 2024

All-cause hospitalization (HR: 2.31, 95%CI: 2.04 – 2.62, p&lt;0.001), heart failure hospitalization (HR: 2.22, 95%CI: 1.92 – 2.55, p&lt;0.001), acute myocardial infarction (HR: 2.06, 95%CI: 1.79 – 2.35, p&lt;0.001), unstable angina (HR: 2.28, 95%CI: 1.72-3.04,

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40